This subgroup analysis of SUSTAIN-3 (NCT02782104), an open-label extension study of esketamine nasal spray (ESK), assessed the long-term safety of flexibly dosed ESK in combination with a...
An analysis of 4 randomized, placebo-controlled trials evaluating a 14-day treatment course of zuranolone 30- or 50-mg in adults with MDD showed nominally significant improvements (p
...
Incidence of akathisia was higher for cariprazine than placebo, with lower incidence observed for patients treated with cariprazine 1.5mg/d+ADT versus 3mg/d+ADT, suggesting dose related e...
This poster is part of the requirement in fulfillment of a Doctor of Nursing Practice (DNP) degree at Rutgers University, School of Nursing. The purpose of the project is to improve the s...
AXS-05 exhibited rapid and sustained improvements in cognitive and physical functioning in individuals with MDD who previously tried one or more prior antidepressants. This study also sho...
Adjunctive therapy with atypical antipsychotics is a treatment option for patients diagnosed with major depressive disorder and inadequate response to antidepressant monotherapy. This cla...
Patients with major depressive disorder often have reduced quality of life. A previous phase 3 trial showed cariprazine adjunctive to antidepressant therapy reduces depressive symptoms in...
In GEMINI, AXS-05, an oral NMDA receptor antagonist approved for MDD, showed significantly higher response rates (defined as 50% reduction in QIDS insomnia score) starting at Week 3 throu...
The Medical Expenditure Panel Survey was used to identify adults with major depressive disorder, to predict the association between health-related quality of life scores and annual health...
This analysis evaluated mania and hypomania across 2 pooled, 6-week, placebo-controlled monotherapy studies; a 6-month open-label extension (OLE) monotherapy study; and a 6-week, placebo-...